<DOC>
	<DOC>NCT01397448</DOC>
	<brief_summary>The primary objective of this study to evaluate the effect of preventing recurrence of gastric or duodenal ulcers by administering E3810 5 mg or 10 mg tablets once daily or Teprenone 150 mg/day (50 mg three times daily) as a control to patients receiving low-dose aspirin and thereby examine the superiority of E3810 over Teprenone.</brief_summary>
	<brief_title>Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Geranylgeranylacetone</mesh_term>
	<criteria>Inclusion Criteria Require longterm administration of lowdose aspirin (81 mg/day or 100 mg/day) Confirmed to have a history of gastric or duodenal ulcer Exclusion Criteria Confirmed to have acute gastro duodenal mucosal lesions, gastric or duodenal ulcer, or upper gastrointestinal (esophagus, stomach, duodenum) bleeding Confirmed to have reflux esophagitis or long segment Barrett's esophagus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Rabeprazole</keyword>
	<keyword>proton pump inhibitor</keyword>
	<keyword>Acetylsalicylic Acid</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Gastric Ulcer</keyword>
	<keyword>Duodenal Ulcer</keyword>
</DOC>